Browse the corpus

Bempedoic acid is a lipid-lowering agent pivotal in managing patients with elevated low-density lipoprotein cholesterol (LDL-C) levels. The U.S. Food and Drug Administration (FDA) has sanctioned its use as an adjunct to maximally tolerated statin therapy for the reduction of LDL-C, specifically in individuals afflicted by atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH). Bempedoic acid is also a viable alternative for patients intolerant to statins. This program discusses the drug's indications, mechanism of action, administration modalities, significant adverse effects, contraindications, and monitoring protocols. The program also addresses monitoring strategies, pharmacokinetic nuances, and associated warnings and precautions. Healthcare providers can adeptly guide patient therapy and manage hyperlipidemia with this knowledge. A thorough understanding of bempedoic acid's intricate pharmacology empowers healthcare professionals to tailor treatment plans based on individual patient requirements. This enables informed decision-making in prescribing, optimizing dosage regimens, and mitigating potential adverse reactions. This activity equips healthcare professionals to deliver evidence-based care to improve outcomes for patients with hypercholesterolemia. Objectives: Identify patients with hyperlipidemia who may benefit from bempedoic acid therapy based on their inadequate response or intolerance to statins. Screen patients for potential contraindications, drug interactions, and adverse effects of bempedoic acid before initiating the therapy. Select the appropriate monitoring strategies to conduct timely follow-up visits, perform necessary laboratory tests, and make medication adjustments to effectively monitor response to bempedoic acid therapy and ensure seamless continuity of care. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from bempedoic acid therapy. Access free multiple choice questions on this topic.

Atherosclerotic cardiovascular disease is the leading cause of death worldwide, with hyperlipidemia being a significant factor associated with an increased risk of cardiovascular disease. Statins are extensively prescribed drugs for treating hyperlipidemia, especially high levels of LDL-C. All healthcare practitioners should be aware of alternative treatments for patients with statin intolerance or familial hypercholesterolemia.[13] Bempedoic acid is a newly approved oral medication designed for additional LDL-C lowering. This drug is an effective monotherapy for patients experiencing statin intolerance or can be co-administered with statins or ezetimibe to enhance its efficacy further.[33][18] Optimal prescribing, dose adjustments, and monitoring for patient response are achieved through effective interprofessional communication among clinicians, pharmacists, and other subspecialists, such as cardiologists and endocrinologists. Coadministration of bempedoic acid with simvastatin at a dose greater than 20 mg and pravastatin at a dose greater than 40 mg is not recommended due to the increased risk of muscle-related adverse effects. Pharmacists are crucial in identifying such interactions and promptly informing the provider. Nursing staff can also contribute by closely monitoring for adverse reactions, providing patient counseling, and acting as a liaison between the pharmacist and the various healthcare providers involved in the patient's care. In conjunction with shared decision-making with the patient, the prescribing clinician should carefully assess the risks versus benefits of bempedoic acid medication. A collaborative interprofessional team approach among clinicians, specialists, nurses, and pharmacists is essential in optimizing bempedoic acid therapy to achieve optimal therapeutic patient outcomes.